Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol: Observational study in young postadolescent women

Paoletti, Anna Maria; Orrù, Marisa; Lello, Stefano; Floris, Stefano; Ranuzzi, F.; Etzi, Rossella; Zedda, Pierina; Guerriero, S.; Fratta, Stefania; Sorge, Roberto; Mallarini, G.; Melis, Gian Benedetto

doi:10.1016/j.contraception.2004.04.004

Cited by 29 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 36 months, BMD (spine, hip, total body) and percent change in BMD did not differ between groups [70]. Martin et al also identified "fair" quality studies comparing COC users to nonhormonal contraception users aged 18-39, followed 6 months to 3 years, and found no difference in BMD between groups [71][72][73][74][75]. In summary, available evidence suggests that COC use has little impact on BMD among adult premenopausal women.…”

Section: Combination Oral Contraceptives (Cocs): Skeletal Impact In Amentioning

confidence: 81%

Update on hormonal contraception and bone density

Isley

Kaunitz

2011

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Combination hormonal contraception and progestin-only contraception (including depot medroxyprogesterone acetate [DMPA]) are effective and convenient forms of reversible contraception that millions of women use worldwide. In recent years, observations of reduced bone mineral density in current users of these methods have led to concerns that this hormone-induced bone loss might translate into long-term increased fracture risk. Special focus has been placed on adolescent users who have not yet attained their peak bone mass as well as perimenopausal users. In 2004, the FDA added a black box warning to DMPA package labeling warning of the risk of significant bone loss and cautioning against long-term use (> 2 years). This article reviews evidence on the use of hormonal contraception and its effect on bone density in adolescent, premenopausal, and perimenopausal populations. Recommendations from reproductive healthcare organizations are reviewed and clinical recommendations are provided.

show abstract

Section: Combination Oral Contraceptives (Cocs): Skeletal Impact In Amentioning

confidence: 81%

Update on hormonal contraception and bone density

Isley

Kaunitz

2011

Rev Endocr Metab Disord

View full text Add to dashboard Cite

show abstract

“…There is some evidence that progestins may also play a role in modifying the estrogenic effect on bone development. 29,30 Although low-dose combined oral contraceptive regimens may diminish the potential physiologic peak in bone density, what this translates to in terms of long-term osteoporosis and fracture risk remains altogether unstudied. Randomized prospective trials will be necessary to help critically assess the impact of low-dose combined oral contraceptive regimens on bone development in adolescents, and long-term follow-up would allow absolute determination of the potential sequelae.…”

Section: Important Unanswered Questionsmentioning

confidence: 99%

Low-dose Oral Contraceptives in Adolescents: How Low Can You Go?

Agostino

Meglio

2010

Journal of Pediatric and Adolescent Gynecology

View full text Add to dashboard Cite

“…They are marketed under different formulations and with different brand names, mainly in Latin America and Asia [47,48]. There are only two studies on the effect of CICs on Nonuser controls [43] Nappi et al 45 ( 1 year BMD. The first was a publication in which 49 users of the CIC containing 50 mg of norethindrone enanthate and 5 mg of estradiol valerate (NET-EN/E 2 Val) [49] were compared with 99 nonusers prior to initiation and at the end of the second year of use.…”

Section: Combined Injectable Contraceptivesmentioning

confidence: 99%

“…summarizes the BMD values of COC users from longitudinal studies published in the last 5 years, in which the age of the population and the composition of the COC were stated[25,26,[28][29][30][31][40][41][42][43][44][45].…”

mentioning

confidence: 99%

Does the use of hormonal contraceptives affect bone mineral density?

Bahamondes

2007

Expert Review of Obstetrics & Gynecology

View full text Add to dashboard Cite

There is concern regarding the influence of hormonal contraceptives on bone mineral density (BMD), especially following the alert issued by the US FDA regarding the use of depot-medroxyprogesterone acetate (DMPA). That statement raised the concern, not only for health providers but also for users and potential users, that other combined contraceptives and progestin-only (p-only) contraceptives could have a deleterious effect on BMD. Overall, hormonal and nonhormonal contraceptives are known to have a high impact on the lives and health of women, as well as on public health. The benefits greatly surpass any risks, including the risk of any potential effect on BMD. Although convincing evidence is accumulating that DMPA may cause loss of BMD, most studies evaluating the effects of combined and other p-only contraceptives on BMD have failed to find a strong effect. Some have reported a beneficial effect. However, hormonal contraceptives were not designed to protect bone health and further studies are necessary.

show abstract

Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol: Observational study in young postadolescent women

Cited by 29 publications

References 40 publications

Update on hormonal contraception and bone density

Update on hormonal contraception and bone density

Low-dose Oral Contraceptives in Adolescents: How Low Can You Go?

Does the use of hormonal contraceptives affect bone mineral density?

Contact Info

Product

Resources

About